22943-93-7

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 106-48-9 4-chloro-phenol 
• 1836-74-4 4-(4-chlorophenoxy)nitrobenzene 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 101-79-1 4-amino-4'-chlorodiphenyl ether 
• 463-71-8 thiophosgene 
• 40859-51-6 4-(4-Chloro-phenoxy)-phenylamine; hydrochloride 

Downstream Products

• 36586-75-1 3-[4-(4-Chloro-phenoxy)-phenyl]-1,1-dihexyl-thiourea 
• 36586-78-4 1,1-Dibutyl-3-[4-(4-chloro-phenoxy)-phenyl]-thiourea 
• 237385-62-5 [4-(4-chlorophenoxy)phenyl]thiourea 
• 760214-55-9 1-[4-(4-chloro-phenoxy)-phenyl]-3-cyano-thiourea 
• 55225-61-1 4-(4-chlorophenoxy)-4'-(trifluoromethylthio)thiocarbanilide 
• 55225-63-3 4-(4-chlorophenoxy)-3'-(trifluoromethyl)-5'-nitrocarbanilide 
• 36612-46-1 3-[4-(4-Chloro-phenoxy)-phenyl]-1,1-diethyl-thiourea 

Relevant academic research and scientific papers

GLYT2 MODULATORS

α-, β-, and γ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I

Novel glycine transporter type-2 reuptake inhibitors. Part 1: α-amino acid derivatives

A variety of α-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [ 14C]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) was evaluated. An array of substituents at the chiral center was studied and overall, L-phenylalanine was identified as the preferred amino acid residue. Compounds prepared from L-amino acids were more potent GlyT-2 inhibitors than analogs derived from the corresponding D-amino acids. Introducing an achiral amino acid such as glycine, or incorporating geminal substitution in the α-position, led to a significant reduction in GlyT-2 inhibitory properties.

Novel glycine transporter type-2 reuptake inhibitors. Part 2: β- and γ-amino acid derivatives

Several β- and γ-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [ 14C]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) were evaluated. A range of lipoph

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.

Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.